Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice

Prostate

Volumn 75, Issue 6, 2015, Pages 593-602

  Chen, Ruibao ^a,b   Zhao, Yunqi ^c,f   Huang, Yan ^a,e   Yang, Qiuhong ^c   Zeng, Xing ^a,b   Jiang, Wencong ^d   Liu, Jihong ^b   Brantley Thrasher, J ^a   Laird Forrest, M ^c   Li, Benyi ^a,d  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF KANSAS   (United States)

^d GUANGDONG MEDICAL UNIVERSITY   (China)

^e NANJING MEDICAL UNIVERSITY   (China)

^f KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

cancer therapy; micelle; nanotechnology; p110 ; prostate cancer; TGX221

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; CYCLINE; KI 67 ANTIGEN; NANOCARRIER; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN KINASE B; TGX221; UNCLASSIFIED DRUG; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PYRIMIDINONE DERIVATIVE; TGX 221;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRDU ASSAY; CONJUGATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LNCAP CELL LINE; MALE; MICELLIZATION; MOUSE; NONHUMAN; NUDE MOUSE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; TISSUE SECTION; TUMOR GROWTH; TUMOR MODEL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIGENS, SURFACE; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MICE; MICE, NUDE; MORPHOLINES; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINONES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84925639206     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22941     Document Type: Article

References (43)

1. Kapse-Mistry S, Govender T, Srivastava R, Yergeri M,. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol 2014; 5: 159.
2. Dawidczyk CM, Kim C, Park JH, Russell LM, Lee KH, Pomper MG, Searson PC,. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release 2014; 187: 133-144.
3. Khisamutdinov EF, Jasinski DL, Guo P,. RNA as a boiling-resistant anionic polymer material to build robust structures with defined shape and stoichiometry. ACS Nano 2014; 8 (5): 4771-4781.
4. Liu Y, Solomon M, Achilefu S,. Perspectives and potential applications of nanomedicine in breast and prostate cancer. Med Res Rev 2013; 33 (1): 3-32.
5. Jhaveri AM, Torchilin VP,. Multifunctional polymeric micelles for delivery of drugs and siRNA. Front Pharmacol 2014; 5: 77.
6. Xiong MP, Yanez JA, Remsberg CM, Ohgami Y, Kwon GS, Davies NM, Forrest ML,. Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats. J Control Release 2008; 129 (1): 33-40.
7. Forrest ML, Zhao A, Won CY, Malick AW, Kwon GS,. Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles. J Control Release 2006; 116 (2): 139-149.
8. Forrest ML, Won CY, Malick AW, Kwon GS,. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles. J Control Release 2006; 110 (2): 370-377.
9. Yanez JA, Forrest ML, Ohgami Y, Kwon GS, Davies NM,. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol 2008; 61 (1): 133-144.
10. Klempner SJ, Myers AP, Cantley LC,. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov 2013; 3 (12): 1345-1354.
11. Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E,. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med 2014; 46 (6): 372-383.
12. Zhu Q, Youn H, Tang J, Tawfik O, Dennis K, Terranova PF, Du J, Raynal P, Thrasher JB, Li B,. Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 2008; 27 (33): 4569-4579.
13. Lee SH, Poulogiannis G, Pyne S, Jia S, Zou L, Signoretti S, Loda M, Cantley LC, Roberts TM,. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc Natl Acad Sci USA 2010; 107 (24): 11002-11007.
14. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ,. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008; 454 (7205): 776-779.
15. Jiang X, Chen S, Asara JM, Balk SP,. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem 2010; 285 (20): 14980-14989.
16. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH,. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005; 11 (5): 507-514.
17. Sturgeon SA, Jones C, Angus JA, Wright CE,. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat. Eur J Pharmacol 2008; 587 (1-3): 209-215.
18. Santos NC, Figueira-Coelho J, Martins-Silva J, Saldanha C,. Multidisciplinary utilization of dimethyl sulfoxide: Pharmacological, cellular, and molecular aspects. Biochem Pharmacol 2003; 65 (7): 1035-1041.
19. Zhao Y, Duan S, Zeng X, Liu C, Davies NM, Li B, Forrest ML,. Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm 2012; 9 (6): 1705-1716.
20. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C,. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3 (1): 81-85.
21. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL,. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997; 3 (4): 402-408.
22. Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H,. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 2003; 305 (3): 974-980.
23. Li B, Sun A, Youn H, Hong Y, Terranova PF, Thrasher JB, Xu P, Spencer D,. Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis 2007; 28 (3): 572-583.
24. Sun A, Tawfik O, Gayed B, Thrasher JB, Hoestje S,. Li C, Li B. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. The Prostate 2007; 67 (2): 203-213.
25. Chen R, Zeng X, Zhang R, Huang J, Kuang X, Yang J, Liu J, Tawfik O, Thrasher JB, Li B,. Cav1. 3 channel alpha1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers. Urol Oncol 2014; 32 (5): 524-536.
26. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R,. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006; 103 (16): 6315-6320.
27. Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B,. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 2004; 145 (6): 2941-2949.
28. Liu J, Youn H, Yang J, Du N, Liu J, Liu H, Li B,. G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells. The Prostate 2011; 71 (12): 1276-1286.
29. Lupold SE, Hicke BJ, Lin Y, Coffey DS,. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002; 62 (14): 4029-4033.
30. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M, Baselga J,. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30 (3): 282-290.
31. Rodon J, Brana I, Siu LL, De Jonge MJ, Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, Eskens F, Bendell JC,. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014; 32 (4): 670-681.
32. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Brana I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, Xu Y, Egile C, Edelman G,. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2014; 20 (1): 233-245.
33. Dienstmann R, Rodon J, Serra V, Tabernero J,. Picking the point of inhibition: A comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther 2014; 13 (5): 1021-1031.
34. Certal V, Carry JC, Halley F, Virone-Oddos A, Thompson F, Filoche-Romme B, El-Ahmad Y, Karlsson A, Charrier V, Delorme C, Rak A, Abecassis PY, Amara C, Vincent L, Bonnevaux H, Nicolas JP, Mathieu M, Bertrand T, Marquette JP, Michot N, Benard T, Perrin MA, Lemaitre O, Guerif S, Perron S, Monget S, Gruss-Leleu F, Doerflinger G, Guizani H, Brollo M, Delbarre L, Bertin L, Richepin P, Loyau V, Garcia-Echeverria C, Lengauer C, Schio L,. Discovery and optimization of pyrimidone indoline amide PI3Kbeta inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers. J Med Chem 2014; 57 (3): 903-920.
35. Bird JE, Smith PL, Bostwick JS, Shipkova P, Schumacher WA,. Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-beta inhibitor in mice. Thromb Res 2011; 127 (6): 560-564.
36. Ristau BT, O'Keefe DS, Bacich DJ,. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol 2014; 32 (3): 272-279.
37. Yang J, Xie SX, Huang Y, Ling M, Liu J, Ran Y, Wang Y, Thrasher JB, Berkland C, Li B,. Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. Nanomedicine 2012; 7 (9): 1297-1309.
38. Troyer JK, Beckett ML, Wright GL, Jr,. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995; 62 (5): 552-558.
39. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM, Jr., Wang CY, Haas GP,. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006; 30 (4): 628-636.
40. Cetnar JP, Beer TM,. Personalizing prostate cancer therapy: the way forward. Drug Discov Today 2014; 19 (9): 1483-1487.
41. Fraser M, Berlin A, Bristow RG, van der Kwast T,. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol 2014; S1078-1439(13)00462-00466.
42. Bitting RL, Armstrong AJ,. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer 2013; 20 (3): R83-R99.
43. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C Koutcher, Scher H, Scardino PT, Rosen N, Sawyers CL,. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19 (5): 575-586.